Evaluating and Improving Outcomes of Gastric Cancer Surgery

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (15 February 2023) | Viewed by 3043

Special Issue Editors


E-Mail Website
Guest Editor
Sunnybrook Health Sciences Centre, University of Toronto, ICES, Ontario Health – Cancer Care Ontario, Toronto, ON M5G 2L7, Canada
Interests: HPB care; upper gastrointestinal (GI) cancers care; GI surgical outcomes and survival; Hepatobiliary surgical outcomes and survival; cancer; clinical guidelines; surgery; health care quality; health economics; quality standards

E-Mail Website
Guest Editor
Department of Community Health Sciences, University of Manitoba, Winnipeg MB R3T 2N2, Canada
Interests: cancer; health equity; health services research; mental health

E-Mail Website
Guest Editor
Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 2Y9, Canada
Interests: cancer; health equity; health services research; mental health

Special Issue Information

Dear Colleagues,

From a Western perspective, gastric cancer patients often present at an advanced stage and with a poor prognosis, resulting in limited treatment options. In North America, this leads to a 25% 5-year survival for gastric cancer patients. While surgical resection remains the cornerstone for curative intervention, there have been notable advancements in the treatment of gastric cancer over the past decade that have resulted in more favorable outcomes and prolonged survival.

This Special Edition aims to summarize our current understanding of gastric and gastroesophageal cancer and examine advancements in surgical treatment modalities and outcomes of these diseases.

Dr. Natalie Groce Coburn
Dr. Alyson Mahar
Dr. Stephanie Snow
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • esophageal cancer
  • gastroesophageal cancer
  • surgical oncology
  • surgical resection
  • surgical intervention
  • cancer outcomes
  • survival outcomes
  • surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1415 KiB  
Article
Laparoscopic versus Open Total Gastrectomy for Locally Advanced Gastric Cancer: Short and Long-Term Results
by Sara Di Carlo, Leandro Siragusa, Alessia Fassari, Enrico Fiori, Francesca La Rovere, Paolo Izzo, Valeria Usai, Giuseppe Cavallaro, Marzia Franceschilli, Sirvjo Dhimolea and Simone Sibio
Curr. Oncol. 2022, 29(11), 8442-8455; https://doi.org/10.3390/curroncol29110665 - 6 Nov 2022
Cited by 8 | Viewed by 2028
Abstract
Background: Laparoscopic gastrectomy for early gastric cancer is widely accepted and routinely performed. However, it is still debated whether the laparoscopic approach is a valid alternative to open gastrectomy in advanced gastric cancer (AGC). The aim of this study is to compare short-and [...] Read more.
Background: Laparoscopic gastrectomy for early gastric cancer is widely accepted and routinely performed. However, it is still debated whether the laparoscopic approach is a valid alternative to open gastrectomy in advanced gastric cancer (AGC). The aim of this study is to compare short-and long-term outcomes of laparoscopic (LG) and open (OG) total gastrectomy with D2 lymphadenectomy in patients with AGC. Methods: A retrospective comparative study was conducted on patients who underwent LG and OG for ACG between January 2015 and December 2021. Primary endpoints were the following: recurrence rate, 3-year disease-free survival, 3-year and 5-year overall survival. Univariate and multivariate analysis was conducted to compare variables influencing outcomes and survival. Results: Ninety-two patients included: fifty-three OG and thirty-nine LG. No difference in morbidity and mortality. LG was associated with lower recurrence rates (OG 22.6% versus LG 12.8%, p = 0.048). No differences in 3-year and 5-year overall survival; 3-year disease-free survival was improved in the LG group on the univariate analysis but not after the multivariate one. LG was associated with longer operative time, lower blood loss and shorter hospital stay. Lymph node yield was higher in LG. Conclusion: LG for AGC seems to provide satisfactory clinical and oncological outcomes in medium volume centers, improved postoperative results and possibly lower recurrence rates. Full article
(This article belongs to the Special Issue Evaluating and Improving Outcomes of Gastric Cancer Surgery)
Show Figures

Figure 1

Back to TopTop